Addex Therapeutics Ltd
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $34.19 million
- Book Value:
- Revenue TTM:
- $1.25 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Addex Therapeutics Ltd had its IPO on 2020-01-29 under the ticker symbol ADXN.
The company operates in the Healthcare sector and Biotechnology industry. Addex Therapeutics Ltd has a staff strength of 26 employees.
Shares of Addex Therapeutics Ltd opened at $0.7 at the start of the last trading session i.e. 2023-06-02.
The stocks traded within a range of $0.68 - $0.7, and closed at $0.7.
This is a +0.13% increase from the previous day's closing price.
A total volume of 59,128 shares were traded at the close of the day’s session.
In the last one week, shares of Addex Therapeutics Ltd have slipped by -4.12%.
Addex Therapeutics Ltd's Key Ratios
Addex Therapeutics Ltd has a market cap of $34.19 million, indicating a price to book ratio of 1.4085 and a price to sales ratio of 10.2796.
In the last 12-months Addex Therapeutics Ltd’s revenue was $1.25 million with a gross profit of $-9687235 and an EBITDA of $-21509952. The EBITDA ratio measures Addex Therapeutics Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Addex Therapeutics Ltd’s operating margin was -1707.44% while its return on assets stood at -87.86% with a return of equity of -202.67%.
In Q3, Addex Therapeutics Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a negative 45.1%.
Addex Therapeutics Ltd’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-2.56 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Addex Therapeutics Ltd’s profitability.
Addex Therapeutics Ltd stock is trading at a EV to sales ratio of 2.5393 and a EV to EBITDA ratio of -0.1471. Its price to sales ratio in the trailing 12-months stood at 10.2796.
Addex Therapeutics Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $12.24 million
- Total Liabilities
- $4.13 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Addex Therapeutics Ltd ended 2023 with $12.24 million in total assets and $0 in total liabilities. Its intangible assets were valued at $12.24 million while shareholder equity stood at $7.95 million.
Addex Therapeutics Ltd ended 2023 with $0 in deferred long-term liabilities, $4.13 million in other current liabilities, 652730.00 in common stock, $-346210419.00 in retained earnings and $0 in goodwill. Its cash balance stood at $10.42 million and cash and short-term investments were $10.43 million. The company’s total short-term debt was $285,922 while long-term debt stood at $0.
Addex Therapeutics Ltd’s total current assets stands at $11.70 million while long-term investments were $0 and short-term investments were $3085.00. Its net receivables were $457039.00 compared to accounts payable of $2.99 million and inventory worth $0.
In 2023, Addex Therapeutics Ltd's operating cash flow was $2981.00 while its capital expenditure stood at $580.
Comparatively, Addex Therapeutics Ltd paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Addex Therapeutics Ltd stock is currently trading at $0.7 per share. It touched a 52-week high of $5.45 and a 52-week low of $5.45. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.8 and 200-day moving average was $0.95 The short ratio stood at 0.43 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 2074.3% are held by institutions.
Frequently Asked Questions About Addex Therapeutics Ltd
Similar Industry Stocks (Biotechnology)
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot”Marie”Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.